Onglyza Pancreatic Cancer

Published on May 4, 2015 by Sandy Liebhard

Text-Size:A A A+

Research has suggested that incretin mimetics like Onglyza may be associated with an increased risk of pancreatic cancer. In 2013, the U.S. Food & Drug Administration announced that it would be reviewing this class of Type 2 diabetes medications after one study linked the drugs to precancerous changes in the cells of the pancreas, and since then a number of incretin mimetic manufacturers have faced legal actions over the drugs’ alleged connection to this potentially deadly form of cancer. You may be entitled to file an Onglyza pancreatic cancer lawsuit if you or a loved one were diagnosed with this disease after you began taking the medication to treat Type 2 diabetes.

Onglyza and the Pancreas

Onglyza (saxagliptin) and Kombiglyze XR (saxagliptin and metformin HCl extended-release) are Type 2 diabetes treatments developed and marketed by Bristol-Myers Squibb and AstraZeneca. The drugs work by regulating the levels of insulin the body produces after meals. Onglyza is sometimes used in combination with other diabetes medications.

onglyza cancer lawsuitIn November 2011, information about a possible association between Onglyza and pancreatitis was added to the drug’s label, after the FDA became aware of patients who had developed acute pancreatitis while using the medication. Pancreatitis is an inflammation of the pancreas that sometimes requires hospitalization and can lead to death. It is also a known risk factor for pancreatic cancer. Patients being treated with Onglyza should contact their healthcare provider if they experience any of the following symptoms:

  • Pain in the upper abdomen
  • Abdominal pain that radiates to your back
  • Abdominal pain that feels worse after eating
  • Nausea and/or vomiting
  • Abdomen is tender to the touch
  • Unexpected weight loss
  • Steatorrhea (oily, smelly stools)

In March 2013, the FDA announced it was reviewing a potential connection between drugs like Onglyza and pancreatic cancer. The announcement followed the publication of a study in the journal Diabetes, which reported that precancerous cells had been discovered in the autopsied pancreases of people taking incretin mimetic drugs. While the FDA has been unable to conclude that Onglyza causes pancreatic cancer, it is continuing to monitor medications in the incretin mimetic class.

Pancreatic cancer is one of the most deadly types of cancer, and ranks as the fourth leading cause of cancer death for both men and women. Symptoms may include:

  • Abdominal pain, often a dull ache in the upper abdomen radiating to the back. The pain may come and go.
  • Bloating or uncomfortable swelling in the abdomen, especially after meals.
  • Nausea
  • Diarrhea
  • Pale colored stools
  • Unexplained weight loss
  • Malaise
  • Loss of appetite
  • Jaundice, a yellowing of skin and/or whites of the eyes

Legal Help for Alleged Victims of Onglyza Pancreatitis

The nationwide law firm of Bernstein Liebhard LLP is currently evaluating potential legal claims on behalf of Onglyza and Kombiglyze XR patients who developed pancreatic cancer. If you would like to learn more about the process for filing an Onglyza pancreatic cancer lawsuit, please call to arrange for a free, no-obligation legal review.

Web Analytics